Table 1 Heterogeneity test statistics (X2) and inconsistency coefficients (I2) for baseline disease characteristics, corresponding to the hazard ratio forest plots of Figures 1 and 2
Baseline disease characteristic | X2(P-value) | I2 |
|---|---|---|
Age (≤60 vs >60) | 1.19 (0.28) | 0.16 |
CR status (CR1 vs CR >1) | 0.12 (0.73) | 0.00 |
Gender (Men vs Women) | 2.06 (0.15) | 0.51 |
Months from current CR to randomization (≤6 vs >6) | 0.01 (0.91) | 0.00 |
Performance status (Normal vs Other) | 0.23 (0.63) | 0.00 |
WBC at diagnosis (109/L) (≤100 vs >100) | 0.13 (0.71) | 0.00 |
Karyotype (SWOG): Favorable (No vs Yes) | 0.31 (0.58) | 0.00 |
Karyotype (SWOG): Intermediate (No vs Yes) | 1.16 (0.28) | 0.14 |
Karyotype (SWOG): Unfavorable (No vs Yes) | 0.07 (0.79) | 0.00 |
AML subtype: M0/M1/M5/M6/M7 (No vs Yes) | 0.60 (0.44) | 0.00 |
AML subtype: M2/M3/M4 (No vs Yes) | 0.14 (0.71) | 0.00 |
Autologous stem cell transplant (No vs Yes) | 1.03 (0.31) | 0.03 |
Extramedullary leukemia (No vs Yes) | 0.12 (0.73) | 0.00 |
High dose of cytarabine received (No vs Yes) | 0.63 (0.43) | 0.00 |
Country (7 countries) | 9.63 (0.14) | 0.38 |
Country (10 countries) | 9.86 (0.36) | 0.09 |